Evidence map›Paper›PMID 36018627›Full record

ArticleJournal of applied clinical medical physics2022

Assessment of using a gamma index analysis for patient-specific quality assurance in Japan.

Yusuke Anetai, Iori Sumida, Yu Kumazaki, Satoshi Kito, Masahiko Kurooka, Yoshihiro Ueda, Yuki Otani, Yuichiro Narita, Ryu Kawamorita, Kazuhiko Akita and 2 more

Abstract read
In one paragraph

Article in Journal of applied clinical medical physics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Dosimetric benefits of half-field arc in prostate cancer treatment.Physical and engineering sciences in medicine · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yusuke AnetaiDepartment of Radiology, Kansai Medical University, Hirakata-shi, Osaka, Japan.
Iori SumidaDepartment of Radiation Oncology, Osaka University Graduate School of Medicine, Suita-shi, Osaka, Japan.
Yu KumazakiDepartment of Radiation Oncology, International Medical Center, Saitama Medical University, Hidaka-shi, Saitama, Japan.
Satoshi KitoDepartment of Radiotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
Masahiko KurookaDepartment of Radiology, Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan.
Yoshihiro UedaDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka-shi, Osaka, Japan.
Yuki OtaniDepartment of Radiology, Kaizuka City Hospital, Kaizuka, Osaka, Japan.
Yuichiro NaritaDepartment of Medical Physics, High Precision Radiation Therapy Center, Aomori Shintoshi Hospital, Aomori-shi, Aomori, Japan.
Ryu KawamoritaDepartment of Radiation Oncology, Tane General Hospital, Osaka-shi, Osaka, Japan.
Kazuhiko AkitaKansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan.
Takahiro KatoDepartment of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Fukushima-shi, Fukushima, Japan.
Mitsuhiro NakamuraDivision of Medical Physics, Department of Information Technology and Medical engineering, Human Health Sciences, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.

Funding

Japan Society of Medical Physics
6 · The paper itself

Abstract

purposeThe Task Group 218 (TG-218) report was published by the American Association of Physicists in Medicine in 2018, recommending the appropriate use of gamma index analysis for patient-specific quality assurance (PSQA). The paper demonstrates that PSQA for radiotherapy in Japan appropriately applies the gamma index analysis considering TG-218. MATERIALS/

methodsThis survey estimated the acceptance state of radiotherapeutic institutes or facilities in Japan for the guideline using a web-based questionnaire. To investigate an appropriate PSQA of the facility-specific conditions, we researched an optimal tolerance or action level for various clinical situations, including different treatment machines, clinical policies, measurement devices, staff or their skills, and patient conditions. The responded data were analyzed using principal component analysis (PCA) and multidimensional scaling (MDS). The PCA focused on factor loading values of the first contribution over 0.5, whereas the MDS focused on mapped distances among data.

resultsResponses were obtained from 148 facilities that use intensity-modulated radiation therapy (IMRT), which accounted for 42.8% of the probable IMRT use in Japan. This survey revealed the appropriate application of the following universal criteria for gamma index analysis from the guideline recommendation despite the facility-specific variations (treatment machines/the number of IMRT cases/facility attributes/responded [representative] expertise or staff): (a) 95% pass rate, (b) 3% dose difference and 2-mm distance-to-agreement, and (c) 10% threshold dose. Conditions (a)-(c) were the principal components of the data by the PCA method and were mapped in a similar distance range, which was easily clustered from other gamma index analytic factors by the MDS method. Conditions (a)-(c) were the universally essential factors for the PSQA in Japan.

conclusionWe found that the majority of facilities using IMRT in each region of Japan complied with the guideline and conducted PSQA with deliberation under the individual facility-specific conditions.

Indexed as

Radiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedHumansJapanQuality Assurance, Health CareRadiotherapy Dosagegamma analysismeasurement-based patient-specific quality assurancemultidimensional scalingprincipal component analysis

Identifiers

PMID36018627
PMCPMC9588274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.